iRhythm Technologies Inc. is a leading digital healthcare company that develops and commercializes wearable biosensors and cloud-based analytics for detecting, predicting, and preventing cardiac diseases. Its flagship Zio platform features an FDA-cleared, CE-marked, wire-free patch-based biosensor that records up to 14 days of continuous electrocardiogram (ECG) data, paired with proprietary AI-driven software that analyzes millions of heartbeats to deliver actionable clinical insights for diagnosing arrhythmias more efficiently than traditional methods. The Zio system supports ambulatory cardiac monitoring, including long-term continuous monitoring (LTCM) and mobile cardiac telemetry, enabling faster detection of conditions like atrial fibrillation across diverse patient populations, including those with cardio-kidney-metabolic diseases. iRhythm Technologies Inc. serves clinicians through services that emphasize patient-centric design, such as home self-application, high analyzable ECG time, and real-world evidence from large-scale studies. Operating in the U.S. core market, innovative channels, and internationally, the company plays a key role in advancing ambulatory ECG monitoring and data-driven cardiac diagnostics.